Meeting Coverage

NGS aligned with FISH for detecting HER2 status in patients with breast cancer, in addition to revealing ERBB2 mutations and nuanced alterations.

Physician’s Weekly spoke with Alexey Danilov, MD, PhD, at ASH 2024 on personalized care and prognostic insights in CLL.

Recent studies, including one from the ASHP Midyear Clinical Meeting, highlight strategies for achieving equitable outcomes in patients with chronic pain.

High tumor-infiltrating lymphocyte levels (>40%) predicted improved survival in triple-negative breast cancer, emphasizing TILs as a key prognostic biomarker.

A recent study evaluated the impact of circulating plasma cells in patients with primary multiple myeloma on bortezomib-containing induction therapy.

A recent study from ASH 2024 examined the clinical features and outcomes of RT in British Columbia, comparing two eras: the chemoimmunotherapy (CIT) era (pre-2016) and the novel agents (NA) era (post-2016).

Educational programs and psychological support addressing cancer-related beliefs and promoting healthier coping strategies are crucial for improving outcomes.

Molecular residual disease was detected about six months before radiographic confirmation of recurrence in patients with inflammatory breast cancer.

New research on breast cancer was presented at the San Antonio Breast Cancer Symposium 2024, including updates on HER2-enriched disease and lymphedema.

Will you be attending “Mind the Gap — Breast Cancer in the Young” at SABCS?

Treatment resistance and toxicity remain critical challenges in managing chronic lymphocytic leukemia (CLL), according to researchers at the ASH Annual Meeting.

Oral oncolytic therapies have revolutionized the treatment of chronic lymphocytic leukemia (CLL), offering improved outcomes and convenience for patients.

Will you be attending the morning symposia, “Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia – What Clinicians Want to Know” at ASH?